Drugs & Targets Gottlieb warns FDA has about one month of user fee funds left January 11, 2019Vol.45 No.02
Drugs & Targets FDA to “take action” against branded drug makers using scare tactics to thwart biosimilar competition January 11, 2019Vol.45 No.02
Drugs & Targets Lynparza gets FDA approval for first-line maintenance in BRCA-mutated advanced ovarian cancer January 04, 2019Vol.45 No.01
Drugs & Targets Sprycel approved in combination with chemo pediatric Ph+ ALL January 04, 2019Vol.45 No.01
Drugs & Targets Keytuda approved for recurrent locally advanced or metastatic MCC January 04, 2019Vol.45 No.01
Drugs & Targets Merck provides update on Keytruda sBLA for KEYNOTE-042 trial January 04, 2019Vol.45 No.01
Drugs & Targets FDA approves longer-acting calaspargase pegol-mknl for ALL January 04, 2019Vol.45 No.01
